Loading clinical trials...
Loading clinical trials...
Phase II Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Conditions
Interventions
Pembrolizumab Injection
Locations
1
United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Start Date
May 11, 2021
Primary Completion Date
April 12, 2024
Completion Date
April 30, 2029
Last Updated
May 29, 2025
NCT07463573
NCT06532279
NCT07209189
NCT06563479
NCT05969860
NCT06731933
Lead Sponsor
Diwakar Davar
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions